The U.S. Food and Drug Administration has approved the first once-weekly basal insulin for adults with type 2 diabetes, offering millions of patients a simpler alternative to daily injections. The decision marks a significant shift in diabetes care, potentially reducing the burden of daily treatment for those struggling with adherence.
The newly approved therapy, a weekly long-acting basal insulin at a concentration of 700 units per milliliter, is indicated as an adjunct to diet and exercise for improving glycemic control. The approval is based on the ONWARDS phase 3a clinical program, which included four randomized, active-controlled trials involving approximately 2,680 adults with uncontrolled type 2 diabetes. Participants used the weekly insulin alongside mealtime insulin, common oral anti-diabetic agents, or GLP-1 receptor agonists. Results showed similar reductions in HbA1c levels compared with daily basal insulin, and the safety profile was consistent with existing daily options.
For patients, the shift from daily to weekly dosing could address a key barrier to consistent care. A study cited in the approval process found that 43.4 percent of type 2 diabetes patients felt burdened by daily treatment, while 28.4 percent reported frequently forgetting to take their medication. Weekly basal insulin is designed to simplify therapy, potentially improving compliance and long-term outcomes. The therapy is approved specifically for adults with type 2 diabetes and is not indicated for type 1 diabetes.
Looking ahead, the weekly insulin is expected to become available in the coming months, with healthcare providers beginning to integrate it into treatment plans for appropriate patients. Novo Nordisk has emphasized its commitment to insulin innovation and access, even as some other companies have scaled back production. For the millions of adults living with type 2 diabetes, this approval represents a step toward more manageable daily life and better blood sugar control.